JAK inhibitors may be effective in controlling chronic mucocutaneous candidiasis, the hyperactivation of the interferon response, that contributes to autoimmunity and autoinflammation, lymphopenia and severe viral and opportunistic infections in STAT1-GOF patients. The gene discussed is STAT1; the disease is Chronic mucocutaneous candidosis.